アブストラクト
| Title | File No.198 卵巣がんにおけるオラパリブの実際 |
|---|---|
| Subtitle | メディカルスクウェア クリニカルポイント |
| Authors | 温泉川真由 |
| Authors (kana) | |
| Organization | がん研究会有明病院 婦人科 兼 総合腫瘍科 |
| Journal | 新薬と臨牀 |
| Volume | 69 |
| Number | 2 |
| Page | 195-200 |
| Year/Month | 2020 / 2 |
| Article | 報告 |
| Publisher | 医薬情報研究所 |
| Abstract | 進行卵巣がんは再発率が高いうえに再発した場合は治癒が困難となるため, 初発患者の再発に対する不安は強い. 昨年6月, 「BRCA遺伝子変異陽性卵巣がんの初回化学療法後の維持療法」の適応追加が承認されたオラパリブには, 卵巣がん患者の5〜10%を占めるとされているBRCA遺伝子変異陽性の進行卵巣がん患者の再発リスクを減らすことが期待されている. 本邦における卵巣がん治療の現状や副作用対策を含めたオラパリブ投与の実際について, がん薬物療法を専門とされ, 卵巣がんの豊富な診療経験をお持ちのがん研究会有明病院婦人科医長 兼 総合腫瘍科副医長の温泉川真由氏にご執筆いただいた. |
| Practice | 臨床医学：一般 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) 国立がん研究センター. がん情報サービスがん登録・統計. https://ganjoho.jp/reg_stat/statistics/stat/summary.html
- 2) Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and pacli-taxel compared with cisplatin and pacli-taxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol. 2003 ; 21(17) : 3194-3200.
- 3) du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/pa-clitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Nat Cancer Inst. 2003 ; 95(17) : 1320-1329.
- 4) Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised con-trolled trial. Lancet. 2009 ; 374(9698) : 1331-1338.
- 5) Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense pa-clitaxel and carboplatin versus conven-tional paclitaxel and carboplatin for treat-ment of advanced epithelial ovarian, fal-lopian tube, or primary peritoneal can-cer(JGOG 3016) : a randomised, con-trolled, open-label trial. Lancet Oncol. 2013 ; 14(10) : 1020-1026.
残りの14件を表示する
- 6) Chan JK, Brady MF, Penson RT, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 ; 374(8) : 738-748.
- 7) Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treat-ment(ICON8) : primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019 ; 394(10214) : 2084-2095.
- 8) Burger RA, Brady MF, Bookman MA, et al. ; Gynecologic Oncology Group. Incor-poration of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 ; 365(26) : 2473-2483.
- 9) Perren TJ, Swart AM, Pfisterer J, et al. ; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 ; 365(26) : 2484-2496.
- 10) Stuart GC, Kitchener H, Bacon M, et al. ; Participants of 4th Ovarian Cancer Con-sensus Conference(OCCC) ; Gyneco-logic Cancer Intergroup. 2010 Gyneco-logic Cancer InterGroup(GCIG)con-sensus statement on clinical trials in ovarian cancer : report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011 ; 21(4) : 750-755.
- 11) Wilson MK, Pujade-Lauraine E, Aoki D, et al. ; Participants of Fifth Ovarian Can-cer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup : recur-rent disease. Ann Oncol. 2017 ; 28(4) : 727-732.
- 12) Enomoto T, Aoki D, Hattori K, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovar-ian cancer : CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA(CHARLOTTE). Int J Gynecol Cancer. 2019 ; 29(6) : 1043-1049.
- 13) Cancer Genome Atlas Research Net-work. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 ; 474(7353) : 609-615.
- 14) Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in plati-num-sensitive relapsed ovarian cancer. N Engl J Med. 2012 ; 366(15) : 1382-1392.
- 15) Pujade-Lauraine E, Ledermann JA, Selle F, et al. ; SOLO2/ENGOT-Ov21 investi-gators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21) : a double-blind, randomised, placebo-con-trolled, phase 3 trial. Lancet Oncol. 2017 ; 18(9) : 1274-1284.
- 16) Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 ; 379(26) : 2495-2505.
- 17) Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 ; 381(25) : 2416-2428.
- 18) Gonzalez-Martin A, Pothuri B, Vergote I, et al. ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 ; 381(25) : 2391-2402.
- 19) Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 ; 381(25) : 2403-2415.
